Detailed role of mesenchymal stem cell (MSC)-derived exosome therapy in cardiac diseases

Area of Science:

• Cardiovascular Research
• Regenerative Medicine
• Cell Biology

Background:

• Coronary heart disease (CHD) remains a primary cause of death, with current treatments unable to prevent cardiomyocyte death from ischemia/reperfusion (I/R) injury.
• Mesenchymal stem cells (MSCs) are explored for cardiac tissue regeneration, but their therapeutic effects stem from secreted factors, not differentiation.
• Exosomes, extracellular vesicles released by MSCs, carry therapeutic cargo like proteins and miRNAs, mediating intercellular communication and tissue repair.

Purpose of the Study:

• To review the therapeutic potential of exosomes derived from mesenchymal stem cells (MSCs) for treating cardiac diseases.
• To highlight the role of exosome-mediated paracrine signaling in cardiac tissue repair following injury.
• To summarize recent advancements in the application of exosomal MSCs in cardiovascular medicine.

Main Methods:

• Review of existing scientific literature on mesenchymal stem cell (MSC) therapy and exosome biology in cardiac contexts.
• Analysis of studies investigating the mechanisms of exosome-mediated intercellular communication in myocardial I/R injury.
• Synthesis of data from animal models demonstrating the therapeutic efficacy of MSC-derived exosomes.

Main Results:

• Mesenchymal stem cell (MSC)-derived exosomes mediate therapeutic effects in various cardiac disease models.
• Exosomes deliver functional molecules (miRNAs, proteins) that promote cardiac tissue healing and reduce cardiomyocyte death.
• The therapeutic benefits of MSCs in cardiac conditions are largely attributable to their secreted exosomes.

Conclusions:

• Mesenchymal stem cell (MSC)-derived exosomes represent a cell-free therapeutic strategy for cardiac diseases.
• Exosomes offer a promising alternative to cell-based therapies, with potential for enhanced safety and efficacy in treating myocardial I/R injury.
• Further research into exosomal MSCs is warranted to advance their clinical application in cardiovascular medicine.